Galmed Pharmaceuticals Ltd (NAS:GLMD)
$ 3.1 -0.02 (-0.64%) Market Cap: 5.17 Mil Enterprise Value: -7.56 Mil PE Ratio: 0 PB Ratio: 0.26 GF Score: 35/100

Q4 2019 Galmed Pharmaceuticals Ltd Earnings Call Transcript

Mar 12, 2020 / 12:30PM GMT
Release Date Price: $610.2 (-19.48%)
Operator

Good day and welcome to Galmed's Fourth Quarter and Full Year 2019 Conference Call. Today's call is being recorded.

Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results, statements and forecasts regarding anticipated time lines and expectations with respect to our regulatory and clinical development programs as well as other statements that relate to future events. These statements are based on the beliefs and expectations of management as of today and actual results, trends, time lines and projections relating to our financial position and projected development programs and pipeline could differ materially. We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC, including, without limitation, the risks under the heading Risk Factors described in our annual report on Form 20-F filed with the SEC and the risks and uncertainties, including in the Form 6-K filed with the SEC earlier today. Galmed assumes no obligation to update any forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot